Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure
暂无分享,去创建一个
Thomas Greenough | Daniel R. Kuritzkes | Mario Stevenson | T. Greenough | D. Kuritzkes | M. Stevenson | R. Gulick | Mark Sharkey | M. Sharkey | Dunja Z. Babič | Dunja Z. Babic | Roy Gulick
[1] John O. Woods,et al. Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy , 2009, Journal of Virology.
[2] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.
[3] S. Frost,et al. Low‐level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T‐cells , 2009, Journal of medical virology.
[4] B. Levine,et al. A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. , 2008, Virology.
[5] J. Lisziewicz,et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.
[6] Sarah Palmer,et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.
[7] John L. Sullivan,et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.
[8] Tara L. Kieffer,et al. Intrinsic Stability of Episomal Circles Formed during Human Immunodeficiency Virus Type 1 Replication , 2002, Journal of Virology.
[9] M. Hirsch,et al. Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1 , 2005, Antimicrobial Agents and Chemotherapy.
[10] R. Siliciano,et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.
[11] M. Hughes,et al. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. , 2009, The Journal of infectious diseases.
[12] B. Clotet,et al. Viral Evolution during Structured Treatment Interruptions in Chronically Human Immunodeficiency Virus-Infected Individuals , 2002, Journal of Virology.
[13] Claus O. Wilke,et al. Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells , 2006, Journal of Virology.
[14] M. Lederman,et al. The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial , 2010, PLoS medicine.
[15] B. Clotet,et al. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. , 1999, Virology.
[16] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[17] C. Delaugerre,et al. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen , 2010, AIDS.
[18] J. Chermann,et al. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals , 1997, Journal of virology.
[19] S J Gange,et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] Anthony S. Fauci,et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy , 2000, Nature Medicine.
[21] A. Trkola,et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication , 2008, Proceedings of the National Academy of Sciences.
[22] Geneviève Boucher,et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.
[23] M. Nei,et al. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. , 2007, Molecular biology and evolution.
[24] D. Ho,et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. , 2000, The Journal of clinical investigation.
[25] F. Bushman,et al. Human Immunodeficiency Virus cDNA Metabolism: Notable Stability of Two-Long Terminal Repeat Circles , 2002, Journal of Virology.
[26] B. Masquelier,et al. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. , 2010, The Journal of antimicrobial chemotherapy.
[27] O. Lambotte,et al. Lack of evidence for prolonged double-long terminal repeat episomal HIV DNA stability in vivo. , 2007, Journal of acquired immune deficiency syndromes.
[28] Daniel R. Kuritzkes,et al. In Vivo Evidence for Instability of Episomal Human Immunodeficiency Virus Type 1 cDNA , 2005, Journal of Virology.
[29] M. Hughes,et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. , 2007, The Journal of infectious diseases.
[30] D. Richman,et al. 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. , 1994, Virology.
[31] J. Sarria,et al. Recovery of Replication-Competent Residual HIV-1 from Plasma of a Patient Receiving Prolonged, Suppressive Highly Active Antiretroviral Therapy , 2010, Journal of Virology.
[32] M A Nowak,et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Howe,et al. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. , 2008, Virology.
[34] K. Crandall,et al. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. , 2001, The Journal of infectious diseases.
[35] Christos J. Petropoulos,et al. Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism , 2006, Antimicrobial Agents and Chemotherapy.
[36] Alan S. Perelson,et al. Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy , 1999, Journal of Virology.